Last updated: February 21, 2026
What is NDC 64980-0447?
NDC 64980-0447 refers to a specific drug registered under the National Drug Code. According to the FDA database, it corresponds to Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir tablets. This combination is used to treat hepatitis C virus (HCV) genotype 1 infection. The drug is marketed under the brand name Technivie (or Viekira Pak in some formulations), manufactured by AbbVie.
Market Overview
Market Size and Demand
- Global HCV Treatment Market: Valued at approximately $13.8 billion in 2022, projected to reach $19.4 billion by 2027, with a CAGR of 7.1% (Research and Markets, 2022).[1]
- U.S. Market Share: The U.S. accounts for roughly 40% of global demand, driven by high prevalence of HCV and widespread treatment initiatives.
- HCV Genotype 1 Prevalence: Represents approximately 70% of HCV infections worldwide, underscoring the target population for this medication.
Competitive Landscape
- Major Competitors:
- Gilead Sciences' Harvoni (ledipasvir/sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Zepatier (elbasvir/grazoprevir)
- These drugs have simplified HCV treatment regimens, with high cure rates and shorter duration courses.
- Market Differentiation: The combination in NDC 64980-0447 offers high efficacy for genotype 1 but faces competition on price and treatment duration.
Pricing Trends
Historical Pricing Data
- Brand Name Price: Historically, a 12-week course of Viekira Pak (which includes NDC 64980-0447) was priced around $83,319 per cycle in 2016.
- Generic Entry Impact: Introduction of generics has driven prices down, with some discounting to under $40,000 for a treatment course by 2021.
Current Pricing Environment
- Official Wholesale Costs:
- Manufacturer’s suggested retail price (MSRP) ranges from $45,000 to $76,000 per 12-week course, depending on negotiated discounts and rebates.
- Insurance Penetration:
- Commercial insurers negotiate discounts, reducing patient out-of-pocket costs to as low as $10,000–$20,000.
- Medicaid and Medicare programs often pay lower reimbursement rates, around $20,000–$30,000.
Pricing Dynamics
- Price reductions correlate with increased generic competition.
- Rebates and Discounts are common, with payers negotiating for lower prices due to the availability of multiple effective therapies.
- Supply and Demand: As new highly effective alternative therapies enter the market, prices will continue to decline.
Future Price Projections
| Year |
Price Range (Per 12-week course) |
Key Factors |
| 2023 |
$35,000 – $50,000 |
Increased generic availability, payer negotiation pressure |
| 2025 |
$25,000 – $40,000 |
Expansion of biosimilars, further market saturation |
| 2030 |
$20,000 – $30,000 |
Widespread generic use, clinical guidelines favoring shorter courses |
- Assumption: Prices decline 10-15% annually with continued generic and biosimilar market entries.
- Rebates: Larger rebates are expected to maintain utilization despite lower list prices.
Regulatory and Policy Influences
- Patent Expiry: The original patent for Viekira Pak expired in the U.S. in 2022, opening the pathway for generics.
- FDA Approvals: Multiple generic versions approved, with bioequivalent formulations, lowering the therapeutic cost.
- Pricing Regulations: Increasing pressure from payers and policymakers to cap drug prices, potentially accelerating price reductions.
Key Takeaways
- NDC 64980-0447, used for hepatitis C genotype 1, commands high prices historically but faces downward pressure.
- Market share shrinks with emergence of generics; prices could fall below $30,000 within five years.
- Competition from newer, pan-genotypic therapies may further diminish its market relevance.
- Price projections assume continued patent expiry, generic approval, and payer discounting.
- The drug’s role will diminish outside specialized or resistant cases due to cost and alternatives.
FAQs
1. Will the price of NDC 64980-0447 decrease significantly in the next year?
Yes. Entry of generic versions and increased negotiation among payers will likely drive prices down by 10–15% annually.
2. How does this drug compare to newer hepatitis C treatments?
Newer medications have shorter treatment durations, broader genotypic coverage, and similar or higher cure rates, reducing demand for genotype 1-specific drugs like NDC 64980-0447.
3. Are there patents or exclusivity periods affecting price trends?
Patent expiration in the U.S. occurred in 2022, enabling generics, which significantly impact pricing.
4. What are the main factors influencing future prices?
Market competition, regulatory approvals for generics, and insurer-mandated rebates.
5. How does pricing differ across regions?
Prices are generally higher in the U.S. due to less regulation; in other countries with national health services, prices are set via negotiated agreements, typically lower.
References
[1] Research and Markets. (2022). Global Hepatitis C Virus Market Report.
